Risk of Serious Adverse Gastrointestinal Events with Potassium Binders in Hospitalized Patients: A National Study

Jürgen L Holleck; Ling Han; Melissa Skanderson; Lori A Bastian; Craig G Gunderson; Cynthia A Brandt; Melissa Perkal; John J Chang; Kathleen M Akgün

doi:10.1007/s11606-024-08979-1

Risk of Serious Adverse Gastrointestinal Events with Potassium Binders in Hospitalized Patients: A National Study

J Gen Intern Med. 2024 Aug 5. doi: 10.1007/s11606-024-08979-1. Online ahead of print.

Authors

Jürgen L Holleck^{1

2}, Ling Han³, Melissa Skanderson⁴, Lori A Bastian^{3

4}, Craig G Gunderson^{3

4}, Cynthia A Brandt^{4

5}, Melissa Perkal^{6

7}, John J Chang^{3

4}, Kathleen M Akgün^{3

4}

Affiliations

¹ Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. Jurgen.Holleck@yale.edu.
² Department of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA. Jurgen.Holleck@yale.edu.
³ Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
⁴ Department of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA.
⁵ Department of Biomedical Informatics & Data Science, Yale School of Medicine, New Haven, CT, USA.
⁶ Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
⁷ Department of Surgery, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA.

PMID: 39103605
DOI: 10.1007/s11606-024-08979-1

Abstract

Background: Concerns about serious adverse gastrointestinal (GI) events with sodium polystyrene sulfonate (SPS) led to development of two new potassium binders, patiromer and sodium zirconium cyclosilicate (SZC), for treatment of hyperkalemia.

Objective: To compare risk of intestinal ischemia/thrombosis or other serious GI events associated with SPS, patiromer, or SZC in hospitalized patients.

Design: Retrospective cohort study.

Participants: National sample of 3,144,960 veterans hospitalized 2016-2022 in the U.S. Department of Veterans Affairs Healthcare System.

Main measures: Demographics, comorbidities, medications and outcomes were ascertained from the VA Corporate Data Warehouse. Exposures were SPS, patiromer, SZC. Outcomes were 30-day intestinal ischemia/thrombosis, and a composite of intestinal ischemia/thrombosis, peptic ulcer/perforation or bowel resection/ostomy.

Key results: Potassium binders were used during 39,270 (1.3%) hospitalizations: SPS = 30,040 (1.0%), patiromer = 3,750 (0.1%), and SZC = 5,520 (0.2%). Intestinal ischemia/thrombosis occurred with 106/30,040 (0.4%) SPS, 12/3750 (0.3%) patiromer and 24/5520 (0.4%) SZC, vs. 6998/3,105,650 (0.2%) without potassium binder. Adjusted odds ratios (aOR) were 1.40 [95% CI, 1.16 to 1.69] with SPS, 1.36 [CI, 0.79 to 2.36] with patiromer, and 1.78 [CI, 1.21 to 2.63] with SZC exposures. Composite GI adverse events occurred with 754/30,040 (2.5%) SPS, 96/3750 (2.6%) patiromer, 2.6% SZC, vs. 144/5520 (2.4%) without binder; aOR were 1.00 [CI, 0.94 to 1.08] with SPS, 1.08 [CI, 0.89 to 1.32] with patiromer, and 1.08 [CI, 0.93 to 1.27] with SZC exposures. No statistical difference in intestinal ischemia/thrombosis between each new agent and SPS was seen (p = 0.274 for SPS vs. SZC; p = 0.916 for SPS vs. patiromer).

Conclusion: Risk of intestinal ischemia/thrombosis or other serious adverse GI events was low and did not differ across three potassium-binding drugs.

Keywords: cation exchange resins; gastrointestinal disease; medication adverse events.

Grants and funding

CIN 13-407/VA Health Services Research and Development